Atrasentan

Atrasentan (ABT-627) is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA[1].

Product Specifications

CAS Number

[173937-91-2]

Product Name Alternative

ABT-627; (+) -A 127722; A-147627

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Endothelin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Atrasentan.html

Concentration

10mM

Purity

99.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC([C@H]1[C@H](C2=CC=C(C=C2)OC)N(C[C@@H]1C3=CC=C(OCO4)C4=C3)CC(N(CCCC)CCCC)=O)=O

Molecular Formula

C29H38N2O6

Molecular Weight

510.62

Precautions

H302, H315, H319, H335

References & Citations

[1]Yuyama H, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498 (1-3) :171-7.|[2]Banerjee S, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007 Apr 15;67 (8) :3818-26.|[3]Weiss J, et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol. 2011 Oct;68 (4) :1093-8.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Commun Biol. 2022 Jul 28;5 (1) :750.|Eur J Pharmacol. 2019 Jun 5:852:142-150.|J Cell Mol Med. 2025 Apr;29 (8) :e70547.|Department Veterinary Clinical Medicine. University of Illinois. 2015.|J Vet Intern Med. 2015 Nov;29 (6) :1584-94.|Mol Immunol. 2019 Oct:114:10-18.